01—History
Free Cash Flow History
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.
- $644.6M
3 older moves run past ±150% (largest +462.8%); point at, tap or drag across the bars to read one.
02—Ledger
Free Cash Flow, period by period
| Period | Scale | Value | Change | Source |
|---|---|---|---|---|
| FY2025 | $644.6M | +37.6% | 10-K | |
| FY2024 | $468.4M | +25.5% | 10-K | |
| FY2023 | $373.3M | +58.6% | 10-K | |
| FY2022 | $235.3M | −21.0% | 10-K | |
| FY2021 | $298.0M | +462.8% | 10-K | |
| FY2020 | $53.0M | +159.2% | 10-K | |
| FY2019 | −$89.5M | −65.2% | 10-K | |
| FY2018 | −$54.2M | −140.8% | 10-K | |
| FY2017 | $132.7M | +348.0% | 10-K | |
| FY2016 | −$53.5M | −35.7% | 10-K | |
| FY2015 | −$39.4M | +19.3% | 10-K | |
| FY2014 | −$48.9M | +5.3% | 10-K | |
| FY2013 | −$51.6M | +21.4% | 10-K | |
| FY2012 | −$65.7M | −87.0% | 10-K | |
| FY2011 | −$35.1M | +23.7% | 10-K | |
| FY2010 | −$46.0M | −10.6% | 10-K | |
| FY2009 | −$41.6M | — | 10-K |
03—Questions
What is Halozyme Therapeutics's current free cash flow?
Halozyme Therapeutics (HALO) annual free cash flow for 2025 was $644.6M, a 37.62% increase from 2024. Halozyme Therapeutics free cash flow for the quarter ending September 30, 2026 was $255.2M.
What was Halozyme Therapeutics's free cash flow in 2024?
Halozyme Therapeutics annual free cash flow for 2024 was $468.4M, a 25.47% increase from 2023.
What was Halozyme Therapeutics's free cash flow in 2023?
Halozyme Therapeutics annual free cash flow for 2023 was $373.3M, a 58.64% increase from 2022.
What is Halozyme Therapeutics's 5-year free cash flow CAGR?
Halozyme Therapeutics free cash flow grew at a compound annual growth rate (CAGR) of 64.85% from FY2020 to FY2025, going from $53.0M to $644.6M over 5 years.
- Company
- Halozyme Therapeutics
- Ticker
- HALO
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)